Viking Therapeutics logo
Viking Therapeutics
VKTX | NASDAQ
Chart Builder DCF Calculator
$26.80
-$2.42 (-8.28%)
At close: Nov 16, 2026, 4:00 PM ET
$26.73
-$0.07 (-0.26%)
After-hours: Nov 16, 2026, 7:57 PM ET

Viking Therapeutics Company Profile

Company profile explained

Company Profile

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Key Executives

Name Position
Brian Lian President, Chief Executive Officer & Director
Gregory S. Zante Chief Financial Officer
Geoffrey E. Barker Chief Development Officer
Hubert C. Chen Chief Medical Officer
Katherine Mercier Vice President of Quality and Compliance
Kenneth Herman Senior Vice President of Commercial, Marketing & Sales
Michael Morneau Vice President of Finance & Administration
Neil Aubuchon Chief Commercial Officer
Nils U. Olsson Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Oct 29, 2026 10-Q Quarterly Report
Oct 28, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Sep 25, 2026 424B5 Filing
Sep 25, 2026 424B5 Filing
Sep 24, 2026 FWP Filing
Sep 24, 2026 305B2 Filing
Sep 23, 2026 424B5 Filing
Sep 23, 2026 424B5 Filing
Sep 22, 2026 8-K Current Report
View All SEC Filings ➞
Viking Therapeutics
Viking Therapeutics logo
Country United States
IPO Date Apr 28, 2015
Industry Biotechnology
Sector Healthcare
Employees 53
CEO Brian Lian

Contact Details

9920 Pacific Heights Boulevard San Diego, California 92121 United States

Stock Details

Ticker Symbol VKTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001607678
CUSIP Number 92686J106
ISIN Number US92686J1060
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.